Gillen D, Wirz A A, Neithercut W D, Ardill J E, McColl K E
University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK.
Gut. 1999 Apr;44(4):468-75. doi: 10.1136/gut.44.4.468.
Omeprazole has a greater intragastric pH elevating effect in Helicobacter pylori positive than negative subjects. Ammonia production by H pylori has been suggested as a probable mechanism.
To assess the effect of H pylori status on gastric acid secretion during omeprazole treatment, and to examine the possible role of ammonia neutralisation of intragastric acid in increased omeprazole efficacy in infected subjects.
Twenty H pylori positive and 12 H pylori negative healthy volunteers were examined before and six to eight weeks after commencing omeprazole 40 mg/day. On both occasions plasma gastrin and acid output were measured basally and in response to increasing doses of gastrin 17 (G-17). Gastric juice ammonium concentrations were also measured.
Prior to omeprazole, measurements were similar in the H pylori positive and negative subjects. During omeprazole, median basal intragastric pH was higher in the H pylori positive (7.95) versus negative (3.75) subjects (p<0.002). During omeprazole basal, submaximal (180 pmol/kg/h G-17), and maximal acid outputs (800 pmol/kg/h G-17) were lower in H pylori positive subjects (0.0, 3.6, 6.0 mmol/h respectively) versus negative subjects (0.3, 14.2, 18.6 mmol/h) (p<0.03 for each). This effect was not explained by neutralisation by ammonia.
The presence of H pylori infection leads to a more profound suppression of acid secretion during omeprazole treatment. The effect cannot be explained by neutralisation of intragastric acid by bacterial ammonia production and its precise mechanism has to be explained.
奥美拉唑对幽门螺杆菌阳性受试者的胃内pH升高作用比对阴性受试者更强。幽门螺杆菌产生氨被认为是一种可能的机制。
评估幽门螺杆菌状态对奥美拉唑治疗期间胃酸分泌的影响,并探讨氨中和胃内酸在感染受试者中增强奥美拉唑疗效的可能作用。
20名幽门螺杆菌阳性和12名幽门螺杆菌阴性的健康志愿者在开始每天服用40毫克奥美拉唑前以及服药6至8周后接受检查。在这两个时间点,分别基础测定血浆胃泌素和酸分泌量,并测定给予递增剂量胃泌素17(G-17)后的反应。同时还测定胃液铵浓度。
在服用奥美拉唑之前,幽门螺杆菌阳性和阴性受试者的测量结果相似。在服用奥美拉唑期间,幽门螺杆菌阳性受试者的中位基础胃内pH值(7.95)高于阴性受试者(3.75)(p<0.002)。在服用奥美拉唑期间,幽门螺杆菌阳性受试者的基础、次最大剂量(180 pmol/kg/h G-17)和最大酸分泌量(800 pmol/kg/h G-17)(分别为0.0、3.6、6.0 mmol/h)低于阴性受试者(0.3、14.2、18.6 mmol/h)(各p<0.03)。这种效应不能用氨的中和作用来解释。
幽门螺杆菌感染的存在导致在奥美拉唑治疗期间对酸分泌的抑制作用更强。这种效应不能用细菌产生氨中和胃内酸来解释,其确切机制有待阐明。